Novel Antitumor Agents 3

• 7081 7081 通过酶的过度激活靶向异柠檬酸脱氢酶突变 Enzyme hyperactivation to target isocitrate dehydrogenase mutations Erick Gonzalez, Shengqi Hou, Andrew M. Intlekofer
• 7082 · PDF 拟人参皂苷F11增强YBX1介导的PRPS2转录抑制，从而抑制三阴性乳腺癌的干性和肺转移 Pseudoginsenoside F11 enhances YBX1-mediated transcriptional repression of PRPS2 to inhibit the stemness and pulmonary metastasis of triple negative breast cancer Kejia Xu, Huimin Liu, Yuting Bai, Haojie Chen, Yi Liu, Yimeng Liu, Xing Wan, Rong Xiang
• 7083 · PDF ABSK211是一种高效、口服可用的泛KRAS抑制剂，与多种药物联用表现出强大的抗肿瘤疗效 ABSK211, a highly potent and orally available pan-KRAS inhibitor, demonstrates robust antitumor efficacy in combination with multiple agents Qianqian Chen, Bin Shen, Xiao Chen, Jie Wang, Jie Zhang, Manqi Liu, Hongping Yu, Nannan Zhang
• 7084 7084 beta-石竹烯在结肠癌模型中诱导凋亡并抑制血管生成 beta-Caryophyllene induces apoptosis and inhibits angiogenesisin colon cancer models Loiy Ahmed Hassan, Saad Sabbar, Yasser Tabana
• 7085 · PDF Obscurin-PH作为三阴性乳腺癌的化疗增敏剂 Obscurin-PH as a chemo-sensitizer in triple-negative breast cancer Kelly Griffiths, Matthew Eason, Aikaterini Kontrogianni-Konstantopoulos
• 7086 · PDF 一种高效、选择性Werner解旋酶（WRN）抑制剂在低TA重复微卫星高度不稳定（MSI-H）癌症中的活性的临床前特征分析 Preclinical characterization of a potent and selective Werner helicase (WRN) inhibitor with activity in low-TA repeat microsatellite instability-high (MSI-H) cancers Pablo E. Hollstein, Daniel A. Aiello, Anne Y. Saiki, Keegan S. Cooke, Petia Mitchell, Xiang Yi, Ishwar N. Kohale, Matthew J. Rardin, John Rodgers, Mauro Poggio, Chun Su, Sigurgeir Ólafsson, Doruk Beyter, Jennifer A. Roth, Nuria A. Tamayo, Kevin L. Greenman, Andrew J. Holland, Paul E. Hughes
• 7087 · PDF 优化venetoclax-青蒿素偶联物的连接子以改善水溶性和抗白血病效果 Optimizing the linker of venetoclax-artemisinin conjugates to improve water solubility and antileukemia effects Jingyi Zhang, Linghui Hou, Zhenwei Zhang, Samuel Waxman, Linxiang Zhao, Yongkui Jing
• 7088 · PDF NAD(P)H:醌氧化还原酶1（NQO1）：它是结直肠癌中潜在的分子靶点吗？ NAD(P)H: Quinone oxidoreductase 1 (NQO1): Is it a potential molecular target in colorectal cancer? Chaithanya Ganji, Raasil R. Basha, Karthikeya Ganji, Mehmet Akce, Bassel F. El-Rayes
• 7089 · PDF Diphyllin在肝癌中诱导自噬介导的铁死亡 Diphyllin induces autophagy-mediated ferroptosis in liver cancer Jinfang Zhang, Zhanghao Li, Zheng CHEN, Chao Wang, Aiping Lu*
• 7090 · PDF ABSK211的临床前特征分析：一种在KRAS驱动肿瘤中具有广泛而强效活性的高效、口服生物利用度良好且选择性的泛KRAS抑制剂 Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS inhibitor with broad and robust activity in KRAS-driven tumors Yongxian Zhang, Fei Yang, Zhigang Feng, Meimei Sun, Xinyan Huang, Haibing Deng, Hongping Yu, Haiyan Ying
• 7091 · PDF DWP216，一种TEAD1/2抑制剂，通过逆转耐药机制增强多种KRAS抑制剂在RAS依赖性癌症中的疗效 DWP216, a TEAD1/2 inhibitor, enhances efficacy of diverse KRAS inhibitors by reversing resistance mechanisms in RAS-dependent cancers Bora Yoo, Ye Gi Han, Hye-Been Yoo, Ahreum Kwon, Jiyoon Seok, Youngwoo Choi, Ji-Duck Kim, Hyounmie Doh
• 7092 · PDF 具有同类最佳潜力的高效、突变体选择性 p53 Y220C 再激活剂 Highly potent and mutant-selective p53 Y220C reactivators with best-in-class potential Chiou-Hong Lin, Benjamin C. Milgram, Brendon Ladd, Weixue Wang, John P. Vu, Jun Jacob Hu, Yemin Lan, Keyur Gada, Heidi Koldsoe, Stephanie M. Reeve, Robert Hicklin, Mint Sirisawad, Brendan J. Hilbert, Jack A. Henderson, Simon A. Roberts, Gregory Kryukov, Hsu-Ping Kuo, Natasja Brooijmans, Angel Guzman-Perez, Darrin D. Stuart, Erica L. Jackson
• 7093 · PDF MYCN 和 AURKA 双重抑制剂在儿童癌症治疗中的潜在应用 Potential use of MYCN and AURKA dual inhibitors for the treatment of pediatric cancers Nur Awaliyah Mentari Sukma, Wan-Ping Wang, Cheng-Ping Jheng, Chung-Chi Lee, Teng-Kuang Yeh, Jyh-Haur Chern, Ya-Hui Chi
• 7094 · PDF QLS1303 的发现：一种高效、选择性的 KIF18A 抑制剂，在 CIN+ 临床前癌症模型中具有强效抗肿瘤活性 Discovery of QLS1303, a potent and selective KIF18A inhibitor with robust anti-tumor activity in CIN+ preclinical cancer models Fei Chen, Wei Wei, Xiaobing Lv, Xiaoping Zheng, Chen Yang, Lili Fan, Fang Zhang, Junguo Hao, Xinrui Shao, Yan Wu, Ling Li, Ping Chen, Dong Yang, Hua Dong, Guqing Shi, Dongdong Wu, Yanling Xu, Weimei Sun, Liang Xie, Wenyuan Qian, Daqing Sun, Weikang Tao
• 7095 · PDF QLS1403：一种新型高效 PARG 抑制剂，在同源重组缺陷癌症模型中具有强效抗肿瘤疗效 QLS1403, a novel and potent PARG inhibitor with robust anti-tumor efficacy in homologous recombination deficient cancer models Tingting Xia, Wei Wei, Xiaobing Lv, Jianfei Wang, Shengnan Zhang Zhang, Jun Chen, Xianyun Huang, Guozhi Liang, Lan Zhang, Ling Li, Ping Chen, Dong Yang, Fangfang Chen, Guqin Shi, Jiahua Chu, Dongdong Wu, Weimei Sun, Liang Xie, Wenyuan Qian, Daqing Sun, Weikang Tao
• 7096 · PDF 针对 CDH17 的双互补位抗体-药物偶联物的设计与开发 Design and development of a biparatopic antibody-drug conjugate against CDH17 Jinxiu Hou, Lisha Dong, Tingting Gu, Jiyuan Tian, Dandan Liu, Yongxin Shang, Rongmei Yan, Lifeng Pan, Liang Tian, Jian Peng, Zhenping Zhu
• 7097 · PDF GSK5764227（一种新型 B7-H3 导向抗体-药物偶联物（ADC））的非临床表征 Non-clinical characterization of GSK5764227, a novel B7-H3-directed antibody-drug conjugate (ADC) Jeremy Waight, Yuanfeng Zhou, Danni Sun, Lu Zhang, Michael Adam, Dawson Knoblock, Wenjin Zhou, Pengchao Qiu, Jifa Fan, Hannah Chenoweth, Johannes Breuning, Huifeng Niu, Srujana Neelam, Juan Liu, Shannon McKearnan, Natacha Steinckwich-Besancon, Takahiro Sato, Derek Poore, Alexander Cocks, Prajna Behera, Chris Hopson, Kenneth W. Hance, Klaas Bakker
• 7099 · PDF 新型 Ect2-Rac 抑制剂 CPV-337 在乳腺癌和胰腺癌中的应用 Novel Ect2-Rac inhibitor CPV-337 in breast and pancreatic cancer Jessica Colon Gonzalez, Nilmary Grafals-Ruiz, Anamaris Torres-Sanchez, Cornelis Vlaar, Suranganie Dharmawardhane
• 7100 · PDF VS-7375：一种口服、选择性 KRAS G12D 双 ON/OFF 抑制剂，作为单药及与其他药物联用时具有强效抗肿瘤活性 VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents Silvia Coma, Ian Smith, Cristina Caffarra Malvezzi, Clint A. Stalnecker, Emilia Berardelli, Enrico Patrucco, Fusheng Zhou, Channing Der, Chiara Ambrogio, David G. DeNardo, Jonathan A. Pachter
• 7101 · PDF 用于治疗MYC驱动型癌症的首创YTHDC1小分子抑制剂的发现 Discovery of first-in-class YTHDC1 small molecule inhibitors for the treatment of MYC-driven cancers Richard C. Centore, Mark Charles, Mansi Arora, Marius Rebmann, Michael J. Rawling, Jerome Cattin, Xuejing Yang, Emily Batchelor, Matthew Watson, Nagakumar Bharatham, Alexander Howarth, Seema Qamar, Laura Andraghetti, Andrew Seeber, Michael G. Kharas, Sam Cohen, Martin Kulander, Tuomas Knowles, Shilpi Arora
• 7102 · PDF 通过EO-4426双重DNA复制靶向克服胞苷脱氨酶（CDA）介导的耐药：对CDA高表达实体瘤和间充质型GBM的意义 Overcoming cytidine deaminase (CDA) mediated resistance via EO-4426 dual DNA-replication targeting: Implications for CDA-high solid tumors and mesenchymal GBM Jeffrey Bacha, Denni M. Brown, Richard Daniels, Sarath Kanekal, John Langlands
• 7103 · PDF 抗寄生虫药物作为卵巢癌潜在治疗药物的评估 Evaluation of anti-parasitic agents as potential therapeutics in ovarian cancer Aneth Ochoa Negrete, Tiffany Duque, Adithi Kankanala, Gisel Gutierrez, Riyaz Basha
• 7104 · PDF BBO-11818：一种口服生物利用度良好、高效且选择性的非共价泛KRAS(ON)和(OFF)抑制剂，在KRAS突变临床前模型中具有强劲的抗肿瘤活性 BBO-11818: An orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models Carlos E. Stahlhut Espinosa, Anna E. Maciag, Kyle A. Sullivan, Kanchan Singh, Nadege Gitego, Zuhui Zhang, Albert H. Chan, Alok K. Sharma, Patrick Alexander, Jin Shu, Yue Yang, Megan Rigby, Roger Ma, Molly Grandcolas, Saman Setoodeh, Brian P. Smith, Jun Pei, Dana Rabara, Erik K. Larsen, David Turner, Cathy Zhang, Cindy Feng, Siyu Feng, James P. Stice, Rui Xu, Ken Lin, Andrew G. Stephen, Felice C. Lightstone, Chunmei Ji, Keshi Wang, Dhirendra K. Simanshu, Dwight V. Nissley, Eli Wallace, Bin Wang, Kerstin Sinkevicius, Frank McCormick, Pedro J. Beltran
• 7105 · PDF 靶向ADAR1 p150剪接活性的治疗在临床前研究中损伤CD44+ TNBC细胞群 Therapeutic targeting of ADAR1 p150 splicing activity impairs CD44 + TNBC cell populations in preclinical studies Wenxue Ma, Jessica Pham, Emma Klacking, Kendale Wirtjes, Inge van der Werf, Peggy Wentworth, Sheldon Morris, James La Clair, Michael Burkart, Catriona Jamieson
• 7106 · PDF Q-2361，一种用于器官移植受者皮肤癌预防的治疗药物 Q-2361, a treatment for skin cancer prevention in organ transplant recipients Rebecca Pouwer, Kimberley Beaumont, Margaret Veitch, Maria Parra Reyes, Bhanu Chintala, Hui Yi Chew, Peter Soyer, Scott Campbell, James Wells, Andrew Harvey, Terrie-Anne Cock, Brian Dymock
• 7107 · PDF 双重FLT3/BRAF抑制剂PHI3克服FLT3突变型AML中RAS驱动的耐药 Dual FLT3/BRAF inhibitor PHI3 overcomes RAS-driven resistance in FLT3-mutant AML Shikhar Sharma, Anna Skwarska, Evangelia Matenoglou, Sovira Chaudhry, Selvam Murugan, Catherine Smith, Pamela Sung, Eunice Wang, Donald Small, Evripidis Gavathiotis, Marina Konopleva
• 7108 · PDF 通过ivospemin和doxorubicin联合治疗耗竭多胺可导致卵巢肿瘤免疫微环境的改变 Polyamine depletion via ivospemin and doxorubicin combination treatment leads to alterations in the ovarian tumor immune microenvironment Cassandra E. Holbert, Ashley C. Nwafor, Lauren J. Imasa, Robert A. Casero, Tracy Murray Stewart

在会议检索中浏览本分会场